WhatPeptide

Epithalon

A synthetic tetrapeptide associated with pineal peptide research and putative telomerase-related aging hypotheses. Placed on FDA Category 2 list (September 29, 2023) as 'Epitalon.'

Preliminary evidence FDA Category 2 Telomere

Written by WhatPeptide Editorial Team · Last updated 2026-03-17

FDA Category 2 — compounding availability may be limited.

Half-life

Short; clinical pharmacokinetics not well established

Dosage range

5-10 mg daily in short cycles (research context)

Administration

Subcutaneous injection

Research level

Preliminary

How Epithalon works

Epithalon has been reported in preclinical and limited human work to influence telomerase activity and antioxidant gene expression. Mechanistic claims often come from small or regionally published studies with mixed rigor. Large controlled longevity outcomes in humans are not established.

Also known as: Epitalon, Ala-Glu-Asp-Gly

Research relevance

Anti-Aging & Longevity
Moderate relevance 55
Immune Support
Moderate relevance 50
Sleep & Relaxation
Some relevance 45
Cognition & Focus
Some relevance 35
GH Boost
Some relevance 35
Recovery & Healing
Some relevance 30
Hair & Skin
Some relevance 30
Sexual Health
Some relevance 20

Side effects & safety

Injection-site irritation Transient fatigue Headache

Contraindications

Pregnancy
Active cancer history requires specialist input

Consult a healthcare provider before use if any of these apply to you.

Key studies

FAQ

What is Epithalon? +
A synthetic tetrapeptide associated with pineal peptide research and putative telomerase-related aging hypotheses. Placed on FDA Category 2 list (September 29, 2023) as 'Epitalon.' Its mechanism of action is based on preliminary or early-stage research.
What is Epithalon researched for? +
Epithalon has the strongest research relevance for Anti-Aging & Longevity, Immune Support, Sleep & Relaxation. Evidence is based on preliminary or early-stage research.
What are the side effects of Epithalon? +
Reported side effects include Injection-site irritation, Transient fatigue, Headache. Key contraindications: Pregnancy; Active cancer history requires specialist input.
Is Epithalon FDA approved? +
Epithalon is classified as FDA Category 2, meaning compounding availability may be limited.
How is Epithalon administered? +
Epithalon is typically administered via subcutaneous route. Researched dosage range: 5-10 mg daily in short cycles (research context). Half-life: Short; clinical pharmacokinetics not well established.

Explore similar peptides

CJC-1295

Moderate evidence

GH Secretagogue

A modified GHRH analog designed to prolong endogenous GH pulse support through albumin binding (DAC form). Originally placed on FDA Category 2 list (September 2023), then removed September 27, 2024 when the nominator withdrew. FDA still lists it under 'Other bulk drug substances that may present significant safety risks.' Regulatory status remains uncertain.

Ipamorelin

Moderate evidence

Growth Hormone Releasing Peptide

A selective ghrelin-receptor agonist studied for stimulating GH release with less prolactin/cortisol impact than older GHRPs. Originally placed on FDA Category 2 list (September 2023), then removed September 27, 2024 when the nominator withdrew. FDA still lists it under 'Other bulk drug substances that may present significant safety risks.' Regulatory status remains uncertain.

MK-677

Moderate evidence

GH Secretagogue

An oral non-peptide ghrelin receptor agonist often discussed with GH peptides due to GH/IGF-1 stimulating effects. Placed on FDA Category 2 list (September 29, 2023) as 'Ibutamoren mesylate.'

GHRP-2

Moderate evidence

Growth Hormone Releasing Peptide

A potent synthetic GH secretagogue with human endocrine data demonstrating acute GH pulse stimulation.